Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$59.0 million.

  • Indivior Pharmaceuticals' Free Cash Flow fell 108000.0% to -$59.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 14407.41%. This contributed to the annual value of $7.0 million for FY2024, which is 10227.27% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Free Cash Flow of -$59.0 million as of Q3 2025, which was down 108000.0% from $141.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Free Cash Flow registered a high of $141.0 million during Q2 2025, and its lowest value of -$310.0 million during Q4 2023.
  • Over the past 4 years, Indivior Pharmaceuticals' median Free Cash Flow value was -$9.0 million (recorded in 2023), while the average stood at -$11.2 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Free Cash Flow surged by 103333.33% in 2024 and then crashed by 108000.0% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Free Cash Flow stood at -$27.0 million in 2022, then plummeted by 1048.15% to -$310.0 million in 2023, then surged by 89.35% to -$33.0 million in 2024, then crashed by 78.79% to -$59.0 million in 2025.
  • Its last three reported values are -$59.0 million in Q3 2025, $141.0 million for Q2 2025, and $70.0 million during Q1 2025.